Apoptotic MSC (red) being engulfed by a macrophage (green). |
In recent years, significant efforts have been made to develop stem cell-based therapies for difficult-to-treat diseases. MSC therapy is regenerative cell-based therapy for the treatment of these diseases and has shown great promise.
The findings of the BDI study show the therapeutic effects of MSCs are due to the recipient’s immune cells responding to the MSCs undergoing a specific type of cell death, called apoptosis, after injection that brings about anti-inflammatory effects.
Apoptosis is not simply cell death. It is a regulated process that ensures dying cells do not activate unwanted inflammation but instead promote an anti-inflammatory environment.
These apoptotic cells produce extracellular factors that have anti-inflammatory or therapeutic effects which may be possible to harness as alternatives to cell-based therapies.
Led by Associate Professor Tracy Heng, the study found that by disabling apoptosis in MSCs, the cells became ineffective in mitigating disease in models of lung inflammation and multiple sclerosis, diseases in which MSCs are currently being trialed as therapeutic agents.
The findings have now been published in Nature Communications.